Aarey Drugs & Pharmaceuticals Share Price Today

Aarey Drugs AGM passes all resolutions with near-unanimous support

All three AGM resolutions passed with over 99.99% support. Voting on related party transactions excluded promoter votes. Total valid votes for financial adoption reached 9,640,259. Public shareholders approved related party deals unanimously.

Aarey Drugs promoter group stake rises to 41.45% via warrant conversion

Promoter group stake in Aarey Drugs rose to 41.45% after warrant conversions. Total promoter holding increased by 2,370,000 shares to 13,212,443 shares. Nimit Rajesh Ghatalia's individual stake increased to 5.18% of voting capital. Equity share capital of the company expanded to 30,724,303 shares.

Aarey Drugs shares web link for FY26 annual report access

Aarey Drugs notified exchanges of letters sent to shareholders without registered emails. Letters provide web link to access Integrated Annual Report for FY26. Cut-off date for identifying eligible shareholders was September 4, 2026. Disclosure made under Regulation 36(1)(b) of SEBI LODR Regulations. 36th AGM scheduled for September 30, 2026 via video conferencing.

Aarey Drugs Q1 Results: Revenue up 145% YoY, net profit falls 60%

Aarey Drugs & Pharmaceuticals saw revenue surge 145% YoY to ₹4,643.05 lakh in Q1FY26, but net profit before tax fell nearly 60% to ₹51.56 lakh. EPS remained stable at ₹0.36. The Board approved results on August 14, 2026.

Aarey Drugs FY26 net profit rises, revenue falls marginally

Aarey Drugs & Pharmaceuticals reported a net profit of ₹396.76 lakh for FY26, slightly lower than the previous year, while Q4FY26 profit surged to ₹155.74 lakh. Revenue for the year stood at ₹47,226.90 lakh. The board approved the audited results on May 30, 2026, and the company published the extract in newspapers on June 2, 2026.

Aarey Drugs & Pharmaceuticals Submits SEBI Compliance Certificate for Q4 FY26

Aarey Drugs & Pharmaceuticals Limited submitted its Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for Q4 FY26 ended March 31, 2026. The certificate, issued by registrar MUFG Intime India Private Limited, confirms proper handling of dematerialised securities and compliance with prescribed timelines. This regulatory filing demonstrates the pharmaceutical company's commitment to maintaining transparency and adherence to SEBI regulations.